Screener
Bio-Rad Laboratories BIO Q2 2026 earnings
Reported August 4, 2026 · After market close
Revenue$651.0MBeat by $27.0M
EPS$2.62Beat by $0.87
Revenue estimate$624.0M
EPS estimate$1.75
“Second-quarter reported revenue was flat year-over-year, with growth in Clinical Diagnostics offset by continued softness in Life Science. Despite Life Science headwinds, our digital PCR instrument revenue grew more than 20%. EMEA returned to growth, aided by Middle East channel restocking amid continued volatility in the region. During the quarter, we generated $99 million in operating cash flow, and repurchased approximately $32 million of shares. We are reaffirming our full-year outlook, and remain focused on the discipline we believe will drive growth, durable margin expansion, and long-term shareholder value creation.”
Next report
Oct 29, 2026 (in a month)Revenue estimate$650.6M
EPS estimate$2.23
Valuation & ratios
Valuation
as of 09/16/26Versus estimates
Revenue
Diluted EPS
FAQ
- When did Bio-Rad Laboratories report Q2 2026 earnings?
- Bio-Rad Laboratories (BIO) reported Q2 2026 earnings on August 4, 2026 after market close.
- What were Bio-Rad Laboratories's Q2 2026 revenue and EPS?
- Bio-Rad Laboratories reported revenue of $651.0M and eps of $2.62 for Q2 2026.
- Did Bio-Rad Laboratories beat estimates in Q2 2026?
- Revenue beat the consensus estimate of $624.0M by $27.0M. EPS beat the consensus estimate of $1.75 by $0.87.
- How did Bio-Rad Laboratories's Q2 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue declined 0.1% from $651.6M a year earlier and eps grew 0.4% from $2.61.
- Where can I find Bio-Rad Laboratories's Q2 2026 SEC filings?
- You can read the 8-K earnings release (0000012208-26-000046) and the 10-Q periodic report (0000012208-26-000048) directly on SEC EDGAR. The filing index links above go to sec.gov.
